The study that I posted is NOT on IHLs behalf explicitly, because it is a general study that will run for 5 years with 2000 patients. It is Cannvalate standalone study, but looking at what is being tested they are using it as a supplementary study.
The 4 that are being done on IHLs behalf are OSA, TBI, ARDS and TMJ to create novel IP that belongs to IHL.
That big study will help Sud and the Medical Board understand CBD better, and how it affects as mentioned particular things. Some are the focus of our Novel IP, like Sleeping Problems for OSA but the scope of that study is massive and looks at many other conditions like Cancer.
Sud has mentioned in previous interviews before iirc that they will likely be looking at further trials for IHL past these initial 4 further down the road. If all goes well and is a success for IHL, Cannvalate who is currently #1 shareholder would have a far greater stake and the funding given to IHL by oppie conversion would set up IHL with a monster cash balance. Think $20M+ by end of year if all oppies are converted.
Certainly enough to conduct further Trials for any of our successful initial 4 targets and if the team thinks its a good idea they will probably create even more clinical trials to target different areas. But that isnt relevant now, one step at a time first.
